Indications |
Oral Schizophrenia Adult: Initially, 25 mg bid on day 1, increased to 50 mg bid on day 2, 100 mg bid on day 3 and 150 mg bid on day 4. Usual dose range: 300-450 mg daily. Max: 750 mg/day. Elderly: Initially, 25 mg daily, increased in steps of 25-50 mg daily according to response. Renal impairment: Initially, 25 mg daily, may increase in steps of 25-50 mg daily according to response. Hepatic impairment: Dose adjustment may be required. Oral Bipolar disorder Adult: Manic phase: 50 mg bid on day 1, 100 mg bid on day 2, 150 mg bid on day 3 and 200 mg bid on day 4. Usual range: 400-800 mg/day; adjust dose according to response. Dosage increments should be ≤200 mg/day. Depressive phase: Initially, 50 mg at bedtime on day 1; 100 mg on day 2, 200 mg on day 3, and 300 mg on day 4. May increase to 400 mg on day 5 and 600 mg on day 8, if needed. Elderly: Initially, 25 mg daily, increased in steps of 25-50 mg daily according to response. Renal impairment: Initially, 25 mg daily, may increase in steps of 25-50 mg daily according to response. Hepatic impairment: Dose adjustment may be required. Special Populations: Recommended dose for patients with hepatic or renal impairment: Initially, 25 mg daily increased in increments of 25-50 mg daily according to response. |
Contraindications |
Severe CNS depression, bone marrow suppression, coma. |
Warnings / Precautions |
CV disease, cerebrovascular disease or conditions that predispose to hypotension. History of seizures; neuroleptic malignant syndrome; tardive dyskinesia. Monitor glycaemic control, especially in diabetics. Hepatic or renal impairment. Gradual withdrawal is recommended. Monitor for signs of clinical worsening, suicidality or unusual changes in behaviour. Pregnancy and lactation. |
Adverse Reactions |
Headache, asthenia, abdominal pain, back pain, fever, chest pain, postural and orthostatic hypotension, hypertension, constipation, dry mouth, dyspepsia, diarrhoea, leucopenia, elevations in serum transaminase level, weight gain, myalgia, somnolence, dizziness, anxiety, rhinitis, rash, dry skin, ear pain, UTI, syncope, neuroleptic malignant syndrome, variations in WBC count, neutropenia, eosinophilia, elevations in nonfasting serum triglyceride level and total cholesterol, decrease in thyroid hormone levels, prolongation of the QTc interval. |
Overdose Reactions |
Symptoms include drowsiness and sedation, tachycardia and hypotension. |
Drug Interactions |
Increased risk of drowsiness and postural hypotension when used with alcohol. CYP3A4 inducers eg. phenytoin and carbamazepine may decrease plasma levels of quetiapine while CYP3A4 inhibitors eg. ketoconazole and erythromycin may increase its plasma levels. See Below for More quetiapine Drug Interactions |
Mechanism of Actions |
Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain: Serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1 and adrenergic a1 and a2 receptors. It is used in the treatment of schizophrenia and bipolar disorder. Absorption: Well absorbed after oral doses. Distribution: Widely distributed throughout the body. 83% bound to plasma proteins. Metabolism: Extensively metabolised in the liver by sulfoxidation and oxidation. Excretion: Excreted mainly as inactive metabolites. Elimination half-life: about 6-7 hr. |
Administration |
May be taken with or without food. Extended-release: Should be taken on an empty stomach. (Take w/o food or w/ a light meal. Swallow whole, do not chew/crush. ) |
Storage Conditions |
Oral: Store at 25°C. |
ATC Classification |
N05AH04 - quetiapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics. |
Storage |
Oral: Store at 25°C. |
Available As |
|
Quetiapine Fumarate
Post Review about Quetiapine Fumarate Click here to cancel reply.
Quetiapine Fumarate Containing Brands
Quetiapine Fumarate is used in following diseases
Drug - Drug Interactions of Quetiapine Fumarate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.